Serán Bioscience Announces Investment by Vivo Capital A majority investment by Vivo Capital, a healthcare investment firm headquartered in Silicon Valley, will fund the expansion of Serán's service offering, the doubling of clean room capacity by year-end, and the development and construction a new commercial scale cGMP manufacturing facility by the end of 2022. News provided by Share this article Share this article BEND, Ore., Jan. 6, 2021 /PRNewswire/ -- Serán Bioscience today announced that healthcare investment firm Vivo Capital has made a majority investment in Serán alongside Serán's founders who will continue to lead the Company. Founded in 2016, Serán is a leading contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies. Serán's deep experience and expertise in materials science, formulation development, engineering, and pharmaceutical manufacturing enables optimum solutions for their customers most difficult drug development challenges. Serán currently has over 50 employees—of which more than half are scientists—at its facilities in Bend, Oregon.